Seroba Lifesciences is a European life sciences venture capital firm focused on value creation through backing innovations in biotech and medtech.

Seroba Lifesciences

Bpifrance, also known as the Banque publique d'investissement, is a French public sector investment bank formed as a joint venture of two state-owned enterprises: the Caisse des dépôts et consignations and EPIC BPI-Groupe. It has been designated as a Significant Institution and is directly supervised by the European Central Bank.

Bpifrance

Novo Holdings A/S is the holding and investment company responsible for managing the assets and wealth of the Novo Nordisk Foundation, one of the world's largest philanthropic enterprise foundations. It is the controlling shareholder of Novo Nordisk A/S and Novozymes A/S, managing a diverse investment portfolio with a long-term return perspective. The company is a world-leading life sciences investor, with total assets of EUR 108 billion as of year-end 2022.

Novo Holdings A/S

Access Industries is a privately-held industrial group with long-term holdings worldwide. The company's investments span multiple sectors, focusing on established and emerging industries where it can add value and enhance business performance.

Metric
Company Name	Seroba Lifesciences	Bpifrance	Novo Holdings A/S	Access Industries
Symbol
MSH ID	COM:SEROBA-LIFESCIENCES	COM:BPIFRANCE	DK:NOVOHOLDINGS	COM:ACCESSINDUSTRIES
Market	PRIVATE	PRIVATE	PRIVATE	PRIVATE
Sector	Financial Services & Finance	Financial Services & Finance	Healthcare, Finance	Commercial & Professional Services
Industry	Venture Capital	Financial Services & Finance	Life Sciences, Asset Management	Diversified Holdings
Country	IE		DK	US
Stage
Employee Count		1.00K	283	111
Website	seroba-lifesciences.com	bpifrance.com	novoholdings.dk	accessindustries.com
LinkedIn			novo-a-s	access-industries
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	606	707.31K	13.57K	3.62K
Web Traffic Growth	-0.87	0.65	0.10	-0.21
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:SEROBA-LIFESCIENCES

Seroba Lifesciences

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue